Expertise in
3
conditions

Tomoya Miyamura

Fukuoka, JP 
Expertise in
3
conditions
Fukuoka, JP 

Overview

Tomoya Miyamura practices practicing medicine in Fukuoka, Japan.

Mr. Miyamura is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Rheumatoid Lung Disease, Arthritis, and Systemic Lupus Erythematosus (SLE).

He is actively involved in clinical research, co-authoring 49 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Fukuoka, Japan
Other Locations
Chuo, 8108563, Japan
Tokyo, Japan
Yokohama, Japan
Kumamoto, Japan
Meguro, 1528621, Japan
Jigyohama, 8108563, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 2 Less Clinical Trials

49 Total Publications

Joint involvement patterns and patient-reported satisfaction in difficult-to-treat rheumatoid arthritis: results from the multicentre observational cohort, FRANK Registry.
Joint involvement patterns and patient-reported satisfaction in difficult-to-treat rheumatoid arthritis: results from the multicentre observational cohort, FRANK Registry.
Journal: Modern rheumatology
Published: August 04, 2025

Frequently Asked Questions about Tomoya Miyamura

Is Tomoya Miyamura a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Tomoya Miyamura is classified as an Advanced expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tomoya Miyamura participate in research or clinical trials?

Yes. Tomoya Miyamura has published 49 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Tomoya Miyamura's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Miyamura's expertise for a condition
ConditionClose
      View All 21 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile